Reliance Foundation Chairperson Nita Ambani has been named the most powerful businesswoman in Asia by Forbes, leading a list of 50 women leaders from the region that includes eight from India.

Developed markets together now contribute 48% to Lupin's revenue (the bulk, no doubt, coming from the US) and emerging markets another 19%, while the domestic market's share has shrunk to 26 per cent from 31 per cent five years ago.

You would think an average CEO spends a disproportionate amount of time worrying about that fierce archrival! Not really. What about shareholder activism? No way. Then, it must be the quarterly results! Absolutely not.

Newsmakers: Featuring Vinita Gupta, Ashish Bahuguna, Rohit Ohri and others.

Lupin has entered into a strategic asset purchase agreement with Temmler Pharma, a part of the Aenova Group, which is one of the world's largest pharmaceutical contract manufacturers, to acquire its specialty product portfolio.

Lupin claimed the acquisition is largest by a domestic pharma firm in the US. It will help it increase presence in the US and give access to 66 generic drugs.

The acquisition enhances Lupin's scale in the US generic market and also broadens its pipeline in dermatology, controlled substance products and other high-value and niche generics.

Zaxine 550 mg (rifaximin) is a long-term antibiotic treatment drug for adults living with hepatic encephalopathy (HE), a complication of liver disease (cirrhosis).

The drug company had earlier acquired 60 per cent stake in the South African (SA) firm in September, 2008.

Not all Indian bulk drug makers are reeling before the Chinese onslaught. Some have honed their processes to become world leaders in niche areas.

MPW judge Rajiv Memani, CEO of Ernst & Young India talks about Vinita Gupta and why she is among the most powerful women in Indian business.

Daughter of Lupin Ltd founder Deshbhandu Gupta, Vinita Gupta played  major role in establishing her company's presence in the US, the world's largest market for medicines. She aims to reach a revenue target of $5 billion by 2018.

Vinita Gupta took over the reins of Lupin in September 2013 and is now working towards achieving the Mumbai pharma company's projected revenue target of $5 billion by 2018.

Women folk of business families like Godrej, Lupin, Cipla, Emami, Piramal, Sun Pharma and Wockhardt, among many others, are not just part of their respective businesses for namesake but are actively engaged in decision-making riding on their core competence.

The Most Powerful Women in Busines: Repeat winners

Kalpana Morparia, CEO, JPMorgan India, says an ICICI job put her on the path to a corporate career.

The CEO of IL&FS Investment Managers, the private-equity firm that manages assets worth $3.2 billion, easily navigates choppy capital markets.

Under its CEO Schauna Chauhan Saluja's watch, Parle Agro has managed to keep established brands, going strong, while launching new ones.

Her contribution to Lupin Ltd, where she is a director, was best acknowledged when, in an interview in August, her brother Nilesh Gupta, also a director in Lupin, said Vinita was ahead of him in the race to lead the company

The India CEO of the Paris-based IT services company Capgemini reaches home every day by 7.30 pm and gets back to work at 10 pm, answering e-mails and phone calls till half past midnight.